Prostate Health - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The prostate health market size in 2026 is estimated at USD 36.01 billion, growing from 2025 value of USD 32.98 billion with 2031 projections showing USD 55.8 billion, growing at 9.18% CAGR over 2026-2031. This report is Segmented by Disease Indication (Prostate Cancer, Benign Prostate Hyperplasia, Prostatitis), by Product Type (Prescription Drugs, Over-The-Counter Supplements and More), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores and More), Geography (North America, Europe, Asia-Pacific and More). The Report Offers the Value (in USD Million) for the Above Segments.

Global Prostate Health Market Trends and Insights

Aging-Male Population Base Swells Addressable Market

Men 65 years and older are the fastest-growing demographic worldwide and are projected to double in developed economies by 2050. BPH prevalence rises from 50% at age 60 to nearly 90% among men in their 90s, while prostate cancer peaks at 102.8 cases per 100,000 in the 65-74 cohort. This demographic wave heightens absolute patient numbers and per-capita utilization, ensuring structural momentum for the prostate health market.

Growing Use of PSA and mpMRI for Early Detection

MRI-first pathways enable 96% of men with negative scans to avoid biopsy without compromising detection of high-grade cancer over 3 years. Combined PSA-mpMRI screening reduces unnecessary biopsies by up to 50% and is being rapidly integrated into European guideline practice. Such precision approaches strengthen patient confidence and free system resources, boosting adoption across the prostate health market.

Adverse-Event Concerns Around Long-Term 5-ARI Usage

Reports linking 5-ARI therapy to erectile dysfunction and mood disorders temper prescription growth. Physicians increasingly shift toward alpha-blocker combinations or device-based therapies such as UroLift, reallocating share within the prostate health market.

Other drivers and restraints analyzed in the detailed report include:

• Radically Lower Cost of Genomic Testing Enables Risk Stratification
• DTC Tele-Urology Platforms Bundling Meds & Labs
• Low Reimbursement for Precision Diagnostics Outside US/EU

Segment Analysis

BPH captured 46.12% of the prostate health market size in 2025, propelled by lifelong symptom management and broad therapeutic choice. Pharmaceutical and device makers benefit from steady repeat sales and procedure fees. Conversely, prostate cancer posts the fastest trajectory at a 9.98% CAGR on rising genomic-screen uptake and PSMA-targeted radioligand approvals.

Prostatitis remains small but underserved. Emerging microbiota-modifying strategies and localized drug-delivery devices could expand treatment options for patients with chronic pelvic pain and create opportunities for innovators in the prostate health market.

Complete Report Scope:

• By Disease Indication (Value)
  • Benign Prostatic Hyperplasia (BPH)
  • Prostate Cancer
  • Prostatitis
• By Product Type (Value)
  • Prescription Drugs
  • Over-the-Counter Supplements
  • Diagnostics (PSA kits, mpMRI, genomic assays)
  • Minimally-Invasive Devices (laser, RF, prostatic urethral lift)
• By Distribution Channel (Value)
  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Platforms & Tele-urology
• By Geography (Value)
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America held a 38.05% share of the prostate health market in 2025 and is expected to sustain mid-single-digit growth through 2031. Medicare coverage for PSMA-PET imaging, gene panels, and radioligands supports premium-priced interventions while corporate wellness plans foster routine screening. United States direct-to-consumer models normalize online care seeking, boosting adherence and early detection. Canada’s single-payer system emphasizes cost-effectiveness; its approval of oral relugolix demonstrates a willingness to fund drugs that lower hospitalization and injection visits.

The Asia-Pacific region is the fastest-growing region, with a 11.18% CAGR for 2026-2031. Japan and South Korea lead in the adoption of mpMRI and guideline-based care, whereas China and India are experiencing high-volume growth but face gaps in reimbursement and awareness of screening. Governments roll out public-private campaigns, pairing hospital-based “check-up days” with tele-follow-ups to bridge access issues, drawing in multinationals and local startups to the prostate health market.

Europe follows an evidence-centric path that tempers the speed of uptake but ensures durability. Health-technology-assessment agencies tie reimbursement to real-world cost-utility, favoring scans and therapies with demonstrated survival or quality-of-life benefit. Germany and France increasingly rely on multiparametric MRI for biopsy triage, while the United Kingdom’s National Health Service pilots risk-adapted screening.

The Middle East and Africa remain nascent yet promising. Rising life expectancy, private-sector hospital build-outs, and government screening drives create incremental demand. Constraints include low urologist density and fragmented payer systems, but PSMA-PET installations in Gulf Cooperation Council states illustrate gradual capability upgrades.

List of Companies Covered in this Report:

• GlaxoSmithKline
• Pfizer
• Eli Lilly and Company
• Merck
• Abbvie
• Astellas Pharma
• Ipsen
• Ferring Pharmaceuticals
• Boston Scientific
• Teleflex
• Olympus
• NxThera (Medtronic)
• PROCEPT BioRobotics
• Avadel Pharmaceuticals plc
• Urotronic Inc.
• Endo International
• Sanofi
• Bayer
• Nymox Pharmaceutical
• Veracyte (Genomic Health)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support